Skip to Primary Navigation

Skip to main content

FDA reviews PMTA framework amid challenge to tobacco review rule

A photo of a row of brown tobacco leaves hang drying in a wooden barn.
Photo: Carol M. Highsmith/Buyenlarge/Getty Images

Kevin Kinsella

1 min read

The FDA is considering changing to its tobacco product review framework as industry groups challenge the agency’s 2021 PMTA rule in court.

The US Food and Drug Administration (FDA) has announced it is evaluating potential changes to its Premarket Tobacco Product Application (PMTA) regulatory framework as a new court challenge contests key elements of the agency’s tobacco product review process.

The agency said it is reviewing its experience implementing the 2021 and

, , , , ,

Get full access, free for a month

Start your 28-day free trial to continue reading and accessall content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience